Cefatrizine

Cefatrizine
Clinical data
Trade names	Cefaperos, Zanitrin
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral
ATC code	J01DB07 (WHO) ;
Identifiers
	IUPAC name (6R,7R)-7-{[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino}-8-oxo-3-[(1H-1,2,3-triazol-4-ylsulfanyl)methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	51627-14-6 ;
PubChem CID	6410758;
ChemSpider	4918615 ;
UNII	8P4W949T8K;
KEGG	D02711 ;
ChEBI	CHEBI:131730 ;
ChEMBL	ChEMBL1095284 ;
CompTox Dashboard (EPA)	DTXSID7022752 ;
ECHA InfoCard	100.052.096
Chemical and physical data
Formula	C18H18N6O5S2
Molar mass	462.50 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)N)CSc4nn[nH]c4)C(=O)O;
	InChI InChI=1S/C18H18N6O5S2/c19-12(8-1-3-10(25)4-2-8)15(26)21-13-16(27)24-14(18(28)29)9(7-31-17(13)24)6-30-11-5-20-23-22-11/h1-5,12-13,17,25H,6-7,19H2,(H,21,26)(H,28,29)(H,20,22,23)/t12-,13-,17-/m1/s1 ; Key:UOCJDOLVGGIYIQ-PBFPGSCMSA-N ;
	(what is this?) (verify)

Cefatrizine is a first generation broad-spectrum cephalosporin antibiotic^[1] that was developed in the 1970's by GSK plc.^[2] It was sold commercially by Bristol Myers Squibb in France as Cefaperos^[3]^[4] and in Pakistan as Zanitrin,^[4]^[5] though the subject of some clinical trials in the United States,^[6] it was never brought to market there.

References

↑ Dunn GL, Hoover JR, Berges DA, Taggart JJ, Davis LD, Dietz EM, et al. (January 1976). "Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771)". The Journal of Antibiotics. 29 (1). Tokyo: 65–80. doi:10.7164/antibiotics.29.65. PMID 776915.
↑ US 3867380, Dunn GL, Hoover JR, "3-Heterocyclic thio-methylcephalosporins", published 1975-02-18, issued 1975-02-18, assigned to SmithKline Corporation and SmithKline Beecham Corp
↑ "CEFAPEROS 500 mg, gélule" (in French). ANSM. Retrieved August 5, 2026.
1 2 "Bristol-Myers Squibb Co. Form 10-K Annual Report for the Fiscal Year Ended December 31, 1993". U.S. Securities and Exchange Commission. March 31, 1994. Retrieved August 5, 2026.
↑ "Bristol-Myers Squibb Co. Form 10-K Annual Report for the Fiscal Year Ended December 31, 1994". U.S. Securities and Exchange Commission. March 29, 1995. Retrieved August 5, 2026.
↑ Doran RG, Brumfitt W, Hamilton-Miller JM (1976). "Antibacterial Activity of Cefatrizine (BL-S 640), a New Oral Cephalosporin, In Vitro". Antimicrobial Agents and Chemotherapy. 9 (3): 397–402. doi:10.1128/aac.9.3.397. PMC 429517. PMID 1273064.

This systemic antibiotic-related article is a stub. You can help Wikipedia by adding missing information.

[1] Dunn GL, Hoover JR, Berges DA, Taggart JJ, Davis LD, Dietz EM, et al. (January 1976). "Orally active 7-phenylglycyl cephalosporins. Structure-activity studies related to cefatrizine (SK&F 60771)". The Journal of Antibiotics. 29 (1). Tokyo: 65–80. doi:10.7164/antibiotics.29.65. PMID 776915.

[2] US 3867380, Dunn GL, Hoover JR, "3-Heterocyclic thio-methylcephalosporins", published 1975-02-18, issued 1975-02-18, assigned to SmithKline Corporation and SmithKline Beecham Corp

[3] "CEFAPEROS 500 mg, gélule" (in French). ANSM. Retrieved August 5, 2026.

[Bristol_Myers_Squibb_1994-4] 1 2 "Bristol-Myers Squibb Co. Form 10-K Annual Report for the Fiscal Year Ended December 31, 1993". U.S. Securities and Exchange Commission. March 31, 1994. Retrieved August 5, 2026.

[5] "Bristol-Myers Squibb Co. Form 10-K Annual Report for the Fiscal Year Ended December 31, 1994". U.S. Securities and Exchange Commission. March 29, 1995. Retrieved August 5, 2026.

[6] Doran RG, Brumfitt W, Hamilton-Miller JM (1976). "Antibacterial Activity of Cefatrizine (BL-S 640), a New Oral Cephalosporin, In Vitro". Antimicrobial Agents and Chemotherapy. 9 (3): 397–402. doi:10.1128/aac.9.3.397. PMC 429517. PMID 1273064.

[1]

[2]

[3]

[4]

[5]

[6]